Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2026)

Journey Medical has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $122267.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 142.49% year-over-year to $122267.0; the trailing twelve-month figure through Mar 2026 stood at $122267.0 (up 142.49% YoY), and the FY2025 full-year result was $944946.0, down 10.72% from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $122267.0, down from $944946.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $1.1 million in Q4 2024, with the low at $2000.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $426664.3 across 5 years, with a median of $293707.0 in 2022.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures surged 3333.1% — and 2025, when it plunged 76.11%.
• Journey Medical's Gains from Sales and Divestitures stood at $293707.0 in 2022, then soared by 147.61% to $727249.0 in 2023, then jumped by 45.53% to $1.1 million in 2024, then decreased by 10.72% to $944946.0 in 2025, then sank by 87.06% to $122267.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $122267.0 (Q1 2026), $944946.0 (Q4 2025), and $927446.0 (Q3 2025), per Business Quant data.